RET inhibitor for use in treating cancer having a RET alteration
Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
1. A method of treating a subject with a rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC), comprising orally administering to the subject with a RET-altered NSCLC once daily 100 mg to 400 mg of Compound 1, wherein Compound 1 is:
2. The method of claim 1 , wherein the NSCLC is metastatic NSCLC.
3. The method of claim 1 , wherein the NSCLC has a RET mutation or a RET-gene rearrangement.
4. The method of claim 3 , wherein the RET-gene rearrangement is a RET fusion.
5. The method of claim 4 , wherein the RET fusion is selected from the group consisting of KIF5B-RET, CCDC6-RET, NCOA4-RET, TRIM33-RET, KIAA1217-RET, and MPRIP-RET.
6. The method of claim 4 , wherein the RET fusion is KIF5B-RET.
7. The method of claim 4 , wherein the RET fusion is CCDC6-RET.
8. The method of claim 1 , wherein the subject was previously treated with platinum.
9. The method of claim 8 , wherein the subject was previously treated with cisplatin or carboplatin.
10. The method of claim 1 , wherein the subject is orally administered 100 mg of Compound 1 once daily.
11. The method of claim 1 , wherein the subject is orally administered 300 mg of Compound 1 once daily.
12. The method of claim 1 , wherein the subject is orally administered 400 mg of Compound 1 once daily.
13. A method of treating a subject with a rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC), comprising orally administering once daily to the subject with the RET-altered NSCLC one or more solid dosage forms each comprising a pharmaceutically acceptable excipient and 100 mg of Compound 1, wherein Compound 1 is:
14. A method of treating a subject with a metastatic rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC), comprising orally administering to the subject with a RET-altered NSCLC once daily 400 mg of Compound 1, wherein Compound 1 is: